24/7 Market News Snapshot 07 March, 2025 – BioXcel Therapeutics, Inc. Common Stock (NASDAQ:BTAI)

March 7, 2025

DENVER, Colo., 07 March, 2025 (247marketnews.com) – (NASDAQ:BTAI) are discussed in this article.
BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical innovator leveraging artificial intelligence to develop treatments in neuroscience, is experiencing significant momentum in the market. Opening at $2.75 and currently trading at $3.291, this marks a remarkable increase of over 20% from the previous session’s close of $2.740. This impressive price movement, evidenced by a trading volume of 1.67 million shares, reflects a growing investor interest and optimism surrounding the company’s future initiatives. Analysts are noting this surge as a potential breakout and are closely monitoring developments in BioXcel’s product pipeline.

In tandem, BioXcel continues to make strides in its Phase 3 SERENITY At-Home trial, which assesses the safety of BXCL501, an orally dissolving film formulation of dexmedetomidine, specifically for the acute treatment of agitation related to bipolar disorders and schizophrenia. The trial is progressing well, with 33% enrollment achieved as 67 patients have joined across 23 active clinical sites. Top-line results are expected to emerge in the latter half of 2025, potentially supporting a supplemental new drug application (sNDA) aimed at expanding the label of IGALMI® (dexmedetomidine) sublingual film.

CEO Dr. Vimal Mehta highlighted the importance of the trial, noting, “We are pleased with the timely advancement of our SERENITY At-Home trial. It represents the first home-based evaluation of BXCL501, focusing on the lowest approved dose of IGALMI. The safety of our patients remains our foremost objective.” The trial employs a double-blind, placebo-controlled design, intending to enroll 200 patients, each managing their treatments at home over a 12-week period. With approximately 23 million annual episodes of agitation reported among affected individuals, BioXcel Therapeutics is strategically positioned to meet a critical unmet need in this area while advancing its mission to innovate in neuroscience.

Related news for (BTAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.